AZD3293 + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Healthy Japanese Young and Elderly Male and Non-fertile Female Volunteers
Conditions
Healthy Japanese Young and Elderly Male and Non-fertile Female Volunteers
Trial Timeline
Dec 1, 2013 → Jul 1, 2014
NCT ID
NCT02005211About AZD3293 + Placebo
AZD3293 + Placebo is a phase 1 stage product being developed by AstraZeneca for Healthy Japanese Young and Elderly Male and Non-fertile Female Volunteers. The current trial status is completed. This product is registered under clinical trial identifier NCT02005211. Target conditions include Healthy Japanese Young and Elderly Male and Non-fertile Female Volunteers.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02005211 | Phase 1 | Completed |
| NCT01795339 | Phase 1 | Completed |
| NCT01739647 | Phase 1 | Completed |
Competing Products
20 competing products in Healthy Japanese Young and Elderly Male and Non-fertile Female Volunteers
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD0837 | AstraZeneca | Phase 1 | 33 |
| Valsartan | Novartis | Phase 1 | 33 |
| CSL112 + Placebo | CSL | Phase 1 | 32 |
| UT-15C | United Therapeutics | Phase 1 | 30 |
| VNA-318 + Placebo | Biotrial | Phase 1 | 25 |
| Open-label TRV734 125 mg + TRV734 blinded + Oxycodone IR 10 mg + Placebo | Trevena | Phase 1 | 25 |
| TRV130 + Moxifloxacin + Placebo | Trevena | Phase 1 | 25 |
| Radiolabeled TRV130 | Trevena | Phase 1 | 25 |
| TRV130A + Dextrose in Water | Trevena | Phase 1 | 25 |
| TRV734 | Trevena | Phase 1 | 25 |
| ALT02 + EU-licensed Herceptin + US-licensed Herceptin | Alteogen | Phase 1 | 33 |
| ENZ215 + EU Sourced Prolia + US Sourced Prolia | Alkem Laboratories | Phase 1 | 33 |
| KPL-404 | Kiniksa Pharmaceuticals | Phase 1 | 28 |
| MORF-057 + Placebo for MORF-057 | Eli Lilly | Phase 1 | 33 |
| Propranolol + Pseudoephedrine | Eli Lilly | Pre-clinical | 23 |
| LY2157299 | Eli Lilly | Phase 1 | 33 |
| Lasmiditan + Placebo | Eli Lilly | Phase 1 | 33 |
| LY3015014 + Placebo | Eli Lilly | Phase 1 | 33 |
| LOXO-783 | Eli Lilly | Phase 1 | 33 |
| LY2541546 - IV + LY2541546 - SC + Placebo | Eli Lilly | Phase 1 | 33 |